Stephen Farr

Dr. Stephen J.
Farr is a Chairman & Chief Executive Officer at Regel Therapeutics Inc., a Chairman at Cerebral Therapeutics, Inc. and a Member at Royal Pharmaceutical Society of Great Britain.
He is on the Board of Directors at Bright Minds Biosciences, Inc., Zogenix International Ltd., SteadyMed Therapeutics, Inc., Flow Pharma, Inc., ICVRx LLC, Mahzi Therapeutics, Inc., Oscillari LLC, Tevard Biosciences, Inc. and Zogenix Europe Ltd. Dr. Farr was previously employed as an Independent Director by SteadyMed Ltd., a President & Chief Executive Officer by Zogenix, Inc., a Chief Scientific Officer & Senior Vice President by Aradigm Corp., a Professor by Welsh School of Pharmacy, and a Scientific Director by Novo Nordisk A/S.
He received his undergraduate degree from De Montfort University and a doctorate degree from The University of Wales.